Loading Events

« All Events

  • This event has passed.

9th Annual Next Generation Sequencing & Clinical Diagnostics Congress

09/11/2017 - 10/11/2017

Oxford Global Conferences presents its 9th Annual Next Generation Sequencing & Clinical Diagnostics Congress co-located with our 5th Annual Single Cell Analysis Congress and our 3rd Annual Genome Editing Congress, taking place on the 9-10 November 2017, London, UK.

View Agenda here.

Over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organizations as well as leading pharmaceutical and biotech companies.

Over 80 case studies and presentations focused on the developments in NGS technologies, NGS data analysis as well as clinical applications & diagnostics of NGS

3 Congresses in one:

  • 9th Annual Next Generation Sequencing & Clinical Diagnostics Congress
  • 5th Annual Single Cell Analysis Congress
  • 3rd Annual Genome Editing Congress

14 pre-scheduled one to one meetings, exhibition, and informal networking opportunities.

Free Live Webinars 2017:

Advances in NGS Data Analysis

Wednesday 13th September 2017 | 1.30pm BST

Hosted by Stefano Ceri, Polytechnic University of Milan & Jernej Ule, The Francis Crick Institute

Register today for free here. 

Next Generation Sequencing for Liquid Biopsies

Tuesday 26th September 2017 | 2:00 PM

Hosted by Pamela Pinzani, University of Florence & Miika Ahdesmäki, AstraZeneca

Register today for free here.

For further information regarding prices and booking details, please contact Danielle Dalby at d.dalby@oxfordglobal.co.uk or call +44 (0)1865 248 455

Details

Start:
09/11/2017
End:
10/11/2017
Event Category:
Website:
http://www.nextgenerationsequencing-congress.com/

Organizer

Oxford Global Conferences
Website:
http://www.oxfordglobal.co.uk/

Venue

Novotel London West
London, United Kingdom + Google Map

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.